GlassScriptPhysician profile
Virginia Falvello
NPI 1821582545
$579.75
in general payments reported to CMS, 2019-2025
16 companies · $580 in 2025
The $580 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $134.71 | 2025 | Clottriever Bold Catheter |
| Regeneron Healthcare Solutions, INC. | $67.85 | 2025 | Libtayo, Lynozyfic |
| E.R. Squibb & Sons, L.L.C. | $45.83 | 2025 | Opdivo |
| Jazz Pharmaceuticals INC. | $39.98 | 2025 | |
| Agios Pharmaceuticals, INC. | $35.43 | 2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $31.99 | 2025 | Zejula, Jemperli, Blenrep |
| Merck Sharp & Dohme LLC | $28.87 | 2025 | Keytruda Qlex, Lynparza, Keytruda |
| Menarini Silicon Biosystems, INC. | $28.01 | 2025 | |
| Novartis Pharmaceuticals Corporation | $27.17 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.42 | 2025 | Fruzaqla |
| Fresenius Kabi USA, LLC | $22.50 | 2025 | |
| Incyte Corporation | $21.56 | 2025 | Zynyz, Monjuvi |
| Puma Biotechnology, INC. | $19.78 | 2025 | |
| Celgene Corporation | $18.51 | 2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $17.85 | 2025 | Calquence |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $16.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Falvello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.